Ph1-negative chronic granulocytic leukemia: a nonentity

Area of Science:

• Hematology
• Oncology

Background:

• Philadelphia chromosome-positive chronic granulocytic leukemia (CGL) has distinct clinical features.
• Philadelphia chromosome-negative CGL may represent a heterogeneous group of myeloid disorders.
• Accurate diagnosis is crucial for appropriate patient management and prognosis.

Purpose of the Study:

• To re-evaluate the diagnoses of patients initially classified as Philadelphia chromosome-negative CGL.
• To determine the actual nature of these myeloid malignancies.
• To understand the clinical and prognostic implications of misclassification.

Main Methods:

• Retrospective review of 24 patients diagnosed with Philadelphia chromosome-negative CGL between 1976 and 1984.
• Analysis of peripheral blood and bone marrow samples by the Hematology Department at Mayo Clinic.
• Reclassification of initial diagnoses based on updated criteria.

Main Results:

• Of 22 reviewed cases, only a minority retained the CGL diagnosis.
• The majority were reclassified into chronic myelomonocytic leukemia (13 patients), chronic myelomonocytic leukemia in transformation (1 patient), preleukemic syndrome (3 patients), and undifferentiated chronic myeloproliferative disease (5 patients).
• Median survival for the reclassified cohort was 17 months.

Conclusions:

• The diagnosis of Philadelphia chromosome-negative CGL is often inaccurate and masks other myelodysplastic or myeloproliferative neoplasms.
• Accurate subclassification of chronic myeloid disorders is essential for understanding disease biology and patient outcomes.
• This highlights the importance of rigorous diagnostic evaluation in hematologic malignancies.